Loss of Smell (Anosmia/Hyposmia)

Overview

Category: Non-motor symptom (Sensory)

Prevalence: Up to 90%

Detailed Information

Anosmia or hyposmia in PD is caused by alpha-synuclein pathology affecting the olfactory bulb, one of the first brain regions affected according to Braak staging (stage 1). It can precede motor symptoms by 4-8 years or more. Smell testing using standardized instruments such as the UPSIT (University of Pennsylvania Smell Identification Test) or Sniffin' Sticks can support early diagnosis and is increasingly used in research as a prodromal biomarker.

Loss of smell impacts taste perception (which relies heavily on olfactory input), potentially leading to reduced appetite, altered food preferences (tendency toward sweeter or more heavily seasoned foods), weight loss, and nutritional deficiencies. Safety concerns include inability to detect gas leaks, smoke, or spoiled food. Despite its near-universal prevalence in PD, many patients are unaware of their olfactory deficit.

Pathophysiology: Why This Happens

The olfactory bulb and anterior olfactory nucleus are among the earliest central nervous system structures to accumulate alpha-synuclein pathology in PD, corresponding to Braak stage 1 of the ascending pathological progression. Lewy body and Lewy neurite pathology in these structures directly impairs olfactory signal processing.

The olfactory pathway's direct connection to the limbic system (amygdala, entorhinal cortex, hippocampus) without thalamic relay makes it uniquely vulnerable to neurodegenerative pathology. The olfactory epithelium itself (in the nasal cavity) also shows alpha-synuclein deposits, suggesting that the pathological process begins at the peripheral interface between the environment and the nervous system -- supporting the hypothesis that PD pathology may enter the brain through the nasal route.

Dopaminergic neurons within the olfactory bulb (periglomerular cells) are affected, but the olfactory deficit does not respond to levodopa therapy, indicating that the damage extends beyond dopaminergic neurons to include other cell types. The anterior olfactory nucleus, which provides feedback to the olfactory bulb, shows severe neuronal loss in PD, disrupting the normal processing and discrimination of odors.

Prevalence and Demographics

Hyposmia or anosmia affects up to 90% of PD patients when objectively tested, making it the most prevalent non-motor symptom. However, only 28-30% of patients are aware of their olfactory deficit, highlighting the discrepancy between objective and subjective assessment. The prevalence is similar regardless of disease duration, consistent with early involvement.

Prospective studies have demonstrated that individuals with idiopathic hyposmia have a 10-15% risk of developing PD or another synucleinopathy within 5 years. When combined with other prodromal markers (RBD, constipation, depression), olfactory testing contributes to prodromal PD risk stratification. Men are more likely than women to show PD-related olfactory deficits, potentially reflecting sex differences in olfactory bulb vulnerability or baseline olfactory function.

Differential Diagnosis

Several other conditions can cause similar symptoms. A thorough medical evaluation is essential to distinguish Parkinson's-related loss of smell (anosmia/hyposmia) from other causes:

Age-related olfactory decline (presbyosmia) affects approximately 50% of people over age 65 and must be distinguished from PD-related olfactory loss. The degree of olfactory impairment in PD is typically more severe than age-related decline. Post-viral olfactory loss (including post-COVID-19 anosmia) produces a different recovery pattern and may have parosmia (distorted smell) as a distinguishing feature not typically present in PD.

Chronic rhinosinusitis and nasal polyps can cause mechanical obstruction leading to olfactory loss. Head trauma may damage olfactory nerve filaments as they pass through the cribriform plate. Alzheimer's disease causes olfactory dysfunction but with different pathological substrates (amyloid and tau rather than alpha-synuclein). Other neurodegenerative conditions including MSA and DLB also affect smell, consistent with their shared synuclein pathology.

Medications that can impair smell include some antibiotics, calcium channel blockers, and chemotherapy agents. Smoking reduces olfactory function, though paradoxically smoking is associated with reduced PD risk through mechanisms unrelated to olfaction.

How This Symptom Changes by Stage

Olfactory loss is typically already present at the time of PD motor diagnosis (stage 1) and may have been present for years during the prodromal phase. Most patients are unaware of the deficit unless specifically tested. Some patients retrospectively report that food 'doesn't taste the same' or that they stopped enjoying cooking years before motor symptoms appeared.

Throughout stages 2-4, olfactory loss remains relatively stable and does not typically worsen significantly. This plateau effect distinguishes it from most other PD symptoms that progress with disease duration.

In stage 5, olfactory loss is essentially complete (anosmia) in most patients. By this stage, the practical implications primarily relate to nutrition (inability to enjoy food leading to poor intake) and safety (inability to detect environmental hazards).

Stage-by-Stage Quick Reference

A summary of how loss of smell (anosmia/hyposmia) typically presents at each Hoehn & Yahr stage:

Stage 1

Usually already present at diagnosis

Stage 2

Persistent

Stage 3

Stable

Stage 4

Unchanged

Stage 5

Complete anosmia common

Management Strategies

There is currently no effective treatment to restore olfactory function in PD. Levodopa does not improve smell, and no neuroprotective intervention has been shown to prevent olfactory bulb degeneration. However, several management strategies address the consequences of olfactory loss.

Safety measures are essential: install functional smoke detectors on every level of the home, install natural gas and carbon monoxide detectors, label food with clear expiration dates and check dates rather than relying on smell to assess freshness, and use electric stoves rather than gas where possible.

Nutritional strategies include enhancing food flavor through visual presentation, texture variety, and seasoning (emphasizing herbs, spices, and acid rather than salt or sugar). Working with a dietitian can help maintain adequate caloric and nutritional intake when taste-dependent appetite is reduced. Monitoring weight regularly helps identify nutritional decline early.

Smell training (repeated, deliberate sniffing of a set of strong odors daily for several months) has shown modest benefit in post-viral olfactory loss and is being studied in PD. While results in PD are preliminary and less robust than in post-viral loss, the intervention is safe, inexpensive, and may provide marginal benefit.

Olfactory testing with standardized instruments (UPSIT, Sniffin' Sticks) has research value as a prodromal biomarker but currently has limited clinical utility for established PD, as it does not change management. However, it may contribute to early diagnosis in patients with ambiguous symptoms.

Practical Tips

• Install smoke detectors and gas leak detectors for safety
• Use dates on food rather than smell to check freshness
• Add extra seasoning (not salt) to enhance flavor
• Consider dietary counseling if appetite decreases
• Smell training may help some patients

When to See a Doctor

Loss of smell alone is not a reason for urgent medical attention, but mention it at your next neurological visit as it is relevant to PD monitoring.

The Bigger Picture

Loss of smell is the earliest detectable change in the PD brain, present years before the tremor, stiffness, and slowing that bring patients to the neurologist. This makes it both a window into the earliest stages of the disease process and a frustrating example of a symptom for which we have no disease-modifying treatment.

From a research perspective, olfactory testing combined with other prodromal markers (RBD, constipation, family history) is being used to identify individuals at high risk for developing PD before motor symptoms appear. These individuals are the ideal population for neuroprotection trials -- if an intervention could slow or prevent PD, testing it before significant brain damage has occurred offers the best chance of success. The development of alpha-synuclein seed amplification assays (SAA) in nasal brushings represents a potential future breakthrough in using the olfactory system for early PD detection.

For current patients, the practical message is straightforward: compensate for lost smell with technology (detectors), habits (date-checking food), and dietary adjustments (seasoning creatively). These simple measures can prevent the safety hazards and nutritional decline that olfactory loss otherwise causes.